Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
19
1
2020
medline:
28
7
2020
entrez:
19
1
2020
Statut:
ppublish
Résumé
A better understanding of placebo responses and the specific factors influencing these outcomes is important for clinical trial design. We investigated the magnitude of placebo responses at 3 months and the potential factors influencing these outcomes in rheumatoid arthritis (RA) clinical trials. We conducted a systematic review of randomized placebo-controlled trials of pharmacological agents for RA identified from PubMed, Embase, and Cochrane Central Register of Controlled Trials databases. The primary placebo outcome was American College of Rheumatology 20% response rate (ACR20). Data were pooled with a random-effects model. Factors influencing placebo response were assessed by meta-regression analyses. Subgroup analyses were performed for studies conducted in non-Western countries only versus in Western countries (North America and/or Europe) only or both. The meta-analysis included 88 studies comprising 8406 patients receiving a placebo. The pooled estimate of placebo ACR20 was 29.0% (range 10.0-46.2; 95% confidence interval 27.2-30.9). Placebo ACR20 was negatively associated with trials in non-Western (Asian) countries and patient populations showing an inadequate response to biological disease-modifying antirheumatic drugs (DMARDs) in the multivariable analysis, whereas it was positively associated with the year of publication. No background DMARD treatment was also a negative predictor (albeit statistically non-significant). In subgroup analyses of Western and multiregional studies, study population and publication year were significant factors. Our meta-analysis suggests that study location, patient population, and a background DMARD treatment influence placebo ACR20. These along with placebo response temporal profiles have important implications for designing and interpreting RA clinical trials.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
A better understanding of placebo responses and the specific factors influencing these outcomes is important for clinical trial design. We investigated the magnitude of placebo responses at 3 months and the potential factors influencing these outcomes in rheumatoid arthritis (RA) clinical trials.
METHODS
METHODS
We conducted a systematic review of randomized placebo-controlled trials of pharmacological agents for RA identified from PubMed, Embase, and Cochrane Central Register of Controlled Trials databases. The primary placebo outcome was American College of Rheumatology 20% response rate (ACR20). Data were pooled with a random-effects model. Factors influencing placebo response were assessed by meta-regression analyses. Subgroup analyses were performed for studies conducted in non-Western countries only versus in Western countries (North America and/or Europe) only or both.
RESULTS
RESULTS
The meta-analysis included 88 studies comprising 8406 patients receiving a placebo. The pooled estimate of placebo ACR20 was 29.0% (range 10.0-46.2; 95% confidence interval 27.2-30.9). Placebo ACR20 was negatively associated with trials in non-Western (Asian) countries and patient populations showing an inadequate response to biological disease-modifying antirheumatic drugs (DMARDs) in the multivariable analysis, whereas it was positively associated with the year of publication. No background DMARD treatment was also a negative predictor (albeit statistically non-significant). In subgroup analyses of Western and multiregional studies, study population and publication year were significant factors.
CONCLUSIONS
CONCLUSIONS
Our meta-analysis suggests that study location, patient population, and a background DMARD treatment influence placebo ACR20. These along with placebo response temporal profiles have important implications for designing and interpreting RA clinical trials.
Identifiants
pubmed: 31953723
doi: 10.1007/s40261-020-00887-6
pii: 10.1007/s40261-020-00887-6
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-209Références
Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v22-30
pubmed: 22718923
Pain. 2016 Mar;157(3):530-40
pubmed: 26588698
Ann Rheum Dis. 2008 Dec;67(12):1716-23
pubmed: 18541604
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Nat Clin Pract Rheumatol. 2006 Nov;2(11):576-7
pubmed: 17075592
J Pain Res. 2018 Apr 30;11:901-912
pubmed: 29750052
J Psychiatr Res. 2017 Nov;94:202-207
pubmed: 28755620
Arthritis Res Ther. 2014 Jan 03;16(1):101
pubmed: 24387346
Pain. 2015 Dec;156(12):2616-26
pubmed: 26307858
Contemp Clin Trials. 2018 Jan;64:95-100
pubmed: 29101042
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Epilepsia. 2011 Feb;52(2):219-33
pubmed: 21269281
Arthritis Rheum. 1995 Jun;38(6):727-35
pubmed: 7779114
Lancet Psychiatry. 2016 Nov;3(11):1059-1066
pubmed: 27726982
PLoS One. 2013 May 15;8(5):e62599
pubmed: 23690944
Lancet. 2018 Jun 23;391(10139):2503-2512
pubmed: 29908669
Clin Drug Investig. 2013 May;33(5):315-24
pubmed: 23529787
Lancet. 2018 Jun 23;391(10139):2513-2524
pubmed: 29908670
PLoS One. 2018 Feb 28;13(2):e0193043
pubmed: 29489874
Arthritis Rheum. 2008 Nov;58(11):3309-18
pubmed: 18975322
J Rheumatol. 2016 Sep;43(9):1637-42
pubmed: 27422891
Ann Rheum Dis. 2013 Sep 1;72(9):1445-52
pubmed: 23234647
Br J Ophthalmol. 2017 Nov;101(11):1471-1474
pubmed: 28315833
Arthritis Rheum. 2005 Apr;52(4):1031-6
pubmed: 15818698
Ann Intern Med. 2009 Aug 18;151(4):W65-94
pubmed: 19622512
Pain. 2016 Nov;157(11):2617
pubmed: 27755469
Gastroenterology. 2007 Feb;132(2):516-26
pubmed: 17258720
Ann Rheum Dis. 2017 May;76(5):831-839
pubmed: 28087506
Ann Rheum Dis. 2010 Jan;69(1):186-92
pubmed: 19773287
J Manag Care Spec Pharm. 2015 May;21(5):409-23
pubmed: 25943002
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
J Clin Epidemiol. 2002 May;55(5):430-5
pubmed: 12007544
Lancet. 2013 Feb 9;381(9865):451-60
pubmed: 23294500
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25
pubmed: 26545825
Arthritis Res Ther. 2009;11(1):205
pubmed: 19232061
Nat Rev Drug Discov. 2016 May;15(5):305-6
pubmed: 27080040
Mod Rheumatol. 2015 Jan;25(1):21-30
pubmed: 24720551
J Rheumatol. 2020 Jan;47(1):28-34
pubmed: 31043548
Ann Rheum Dis. 2009 Jun;68(6):789-96
pubmed: 19066176
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Ann Rheum Dis. 2015 Feb;74(2):381-8
pubmed: 24285493
Mod Rheumatol. 2013 Jan;23(1):1-7
pubmed: 22772460
Arthritis Rheum. 2003 Jun;48(6):1481-3
pubmed: 12794813
Clin Gastroenterol Hepatol. 2014 Dec;12(12):1981-90
pubmed: 25218669
Mod Rheumatol. 2019 Jan;29(1):31-40
pubmed: 29718746
Parkinsonism Relat Disord. 2016 Aug;29:83-9
pubmed: 27237106
Arthritis Rheumatol. 2014 Jul;66(7):1693-704
pubmed: 24623718